FDA Unveils Plan for Quickening Development of Personalized Therapies

The drugs will target rare diseases, officials said.

The Food and Drug Administration in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

U.S. regulators on Feb. 23 formally unveiled a plan for speeding up the process of bringing drugs aimed at rare diseases to market.

The Food and Drug Administration (FDA) in draft guidance stated that it is proposing to make it easier to secure approval of genome editing and ribonucleic acid-based therapies for rare genetic disorders, or conditions that affect fewer than 200,000 people in the country.